• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Onyx Pharmaceuticals

Onyx Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Bayer Suspends Enrollment for Phase III Trial of Regorafenib for Colorectal Cancer

    Bayer Suspends Enrollment for Phase III Trial of Regorafenib for Colorectal Cancer

  2. Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

    Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

  3. Oxis Biotech Inc. Provides Update for P62-ZZ Multiple Myeloma Patent Application

    Oxis Biotech Inc. Provides Update for P62-ZZ Multiple Myeloma Patent Application

  4. Our Outlook for the Credit Markets

    Rising interest rates have taken their toll, but as the Fed delays dialing back on stimulus, investors are poised to recapture some of their losses.

  5. ClearBridge Fund Prepared for Extended Rally

    The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.

  6. Does This ETF Exceed the Sum of Its Parts?

    We look at how a biotech ETF holds up in an iffy climate for those stocks.

  7. Our Outlook for Health-Care Stocks

    Health-care stocks are on a tear as demand slowly returns.

  8. Our Outlook for Health-Care Stocks

    With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.